Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Gains from Sales and Divestitures (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 104.38% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 104.38% year-over-year, with the annual reading at $1.1 million for FY2025, 104.38% up from the prior year.
  • Gains from Sales and Divestitures hit $1.1 million in Q4 2025 for Compass Therapeutics, up from $823000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.1 million in Q4 2025 to a low of $162000.0 in Q3 2023.
  • Historically, Gains from Sales and Divestitures has averaged $520400.0 across 3 years, with a median of $412500.0 in 2023.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 38.89% in 2024 and later soared 265.78% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $300000.0 in 2023, then skyrocketed by 75.0% to $525000.0 in 2024, then surged by 104.38% to $1.1 million in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for CMPX at $1.1 million in Q4 2025, $823000.0 in Q3 2025, and $823000.0 in Q2 2025.